-
Characteristics No. (%) of subjects
using IUCDNo. (%) of
non-IUCD usersStatistics Age 21–25 35 (23.3) 31 (31.0) 26–30 45 (30.0) 29 (29.0) 31–35 36 (27.0) 13 (13.0) χ2 = 6.48 36–40 23 (15.3) 15 (15.0) p = 0.16 41–45 11 (7.3) 12 (12.0) Total 150 100 Occupation Business 37 (24.7) 41 (41.0) χ2 = 20.2 Employed 51 (34.0) 44 (44.0) p = 0.01 House wife 62 (41.3) 15 (15.0) Total 150 100 Parity 1 25 (16.6) 12 (12.0) 2 52 (34.7) 53 (53.0) χ2 = 8.2 > 3 73 (48.7) 35 (35.0) p = 0.01 Total 150 100 Marital status Single 57 (38.0) 73 (73.0) χ2 = 29.4 Married 93 (62.0) 27 (27.0) p = 0.01 Table 1.
Socio-demographic characteristics of study participants.
-
Variables Adjusted odds
ratio (AOR)95% CI p-value IUCD use 245.56 72.51–831.56 < 0.001 Age 1.00 0.92–1.09 0.946 Single and married 0.62 0.15–2.60 0.512 Employed and business 0.75 0.23–2.48 0.634 Housewife and business 0.21 0.05–0.92 0.038 Parity 0.74 0.44–1.25 0.260 Table 2.
Multivariable logistic regression on vulvovaginal candidiasis (VVC) and IUCD use.
-
IUD usage No. examined No. (%) of subjects with VVC Statistics IUCD group 150 115 (76.6%) χ2 = 53.6 Non-IUCD group 100 30 (30.0%) p < 0.001 Table 3.
Occurrence of VVC among IUCD and non IUCD users.
-
Candida species No. (%) of IUCD
usersNo. (%) of
non-IUCD usersTotal Statistics Candida albicans 50 (43.5) 15 (50) 65 (44.8) χ2 = 55.8 Candida glabrata 22 (19.1) 5 (16.7) 27 (18.6) p = 0.01* Candida krusei 26 (22.6) 8 (26.7) 34 (23.4) Candida tropicalis 17 (14.7) 2 (6.7) 19 (13.1) Total 115 (79.3) 30 (20.7) 145 The symbol * means p is statistically significant. Table 4.
Distribution of Candida species among IUCD and non IUCD users.
-
Duration of use (year) No. examined No. (%) of subjects
with VVCStatistics 0–1 30 16 (53.3) 2–3 60 45 (75.0) χ2 = 19.2 4–5 25 23 (92.0) p = 0.004* > 6 35 31 (88.6) Total 150 115 (76.7) The symbol * means statistically significant. Table 5.
Relationship between duration of IUCD use and VVC infection rate.
-
Candida species No. of isolates
testedNo. (%) of biofilm
positive isolatesStatistics Candida albicans 50 30 (60.0) χ2 = 8.70 Candida glabrata 22 7 (31.8) p = 0.17 Candida krusei 26 10 (38.5) Candida tropicalis 17 8 (47.1) Total 115 55 (47.8) Table 6.
Candida biofilm formation by isolates from IUCD users.
-
Contraceptives No. of subjects No. of subjects
with VVC (%)Statistics Oral contraceptives 70 18 (25.7) χ2 = 1.85 Injectables 8 3 (37.5) p = 0.60 Emergency contraceptives 10 4 (40.0) Norplant implant 12 5 (41.7) Total 100 30 (30.0) Table 7.
Distribution of VVC among non IUCD group on other methods of contraceptives.
-
Symptoms No. (%) of subjects Dysmenorrhoea 9 (6.0) Dyspareunia 11 (7.3) Erosion around the cervix 20 (13.3) Increased menstrual flow 9 (6.0) Decreased menstrual flow 10 (6.7) Genital pruritus 45 (30.0) Vaginal discharge 30 (20.0) Redness of the vulva 16 (10.7) Table 8.
Symptoms of vaginitis among subjects using IUCD.
-
Candida species No. of isolates Antifungal agents tested SDD' (%) No. (%) of isolates resistant (R) Candida albicans 50 Fluconazole 25 (50.0) 25 (50.0) Itraconazole 15 (30.0) 35 (70.0) Voriconazole 0 (0.0) 0 (0.0) Candida glabrata 22 Fluconazole 10 (45.5) 12 (54.5) Itraconazole 8 (36.4) 14 (63.6) Voriconazole 0 (0.0) 0 (0.0) Candida krusei 26 Fluconazole 10 (38.5) 16 (61.5) Itraconazole 8 (30.8) 18 (69.2) Voriconazole 6 (23.1) 0 (0.0) Candida tropicalis 17 Fluconazole 7(41.2) 10(58.8) Itraconazole 6 (35.3) 11 (64.7) Voriconazole 5 (29.4) 0 (0.0) KEY: R (%): Percentage of isolates that were resistant to the antifungal. SDD (%): Percentage of isolates with susceptible dose-dependence (SDD), meaning they require higher doses of the antifungal to be effective. Table 9.
Resistance profile of Candida species isolated from IUCD users with VVC in Calabar.
Figures
(0)
Tables
(9)